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FSH stimulation of granulosa cells (GCs) results in increased hypoxia-inducible factor (HIF)-1 pro-
tein levels and HIF-1 activity that is necessary for up-regulation of certain FSH target genes in-
cluding vascular endothelial growth factor. We report that the role of the phosphatidylinositol
(PI)-3-kinase/AKT pathway in increasing HIF-1 protein in FSH-stimulated GCs extends beyond an
increase inmammalian target of rapamycin-stimulated translation. FSH increases phosphorylation
of the AKT target mouse double-minute 2 (MDM2); a phosphomimetic mutation of MDM2 is
sufficient to induce HIF-1 activity. The PI3-kinase/AKT target forkhead box-containing protein O
subfamily 1 (FOXO1) also effects the accumulation of HIF-1 as evidenced by the ability of a
constitutively active FOXO1 mutant to inhibit the induction by FSH of HIF-1 protein and HIF-1
activity. Activation of the PI3-kinase/AKT pathway in GCs by IGF-I is sufficient to induce HIF-1
proteinbut surprisingly notHIF-1 activity. HIF-1 activity also appears to require a PD98059-sensitive
protein (kinase) activity stimulated by FSH that is both distinct from mitogen-activated ERK ki-
nase1/2 or 5 and independent of the PI3-kinase/AKT pathway. These results indicate that FSH-
stimulatedHIF-1 activation leading toup-regulationof targets such as vascular endothelial growth
factor requires not only PI3-kinase/AKT-mediated activation ofmammalian target of rapamycin as
well as phosphorylation of FOXO1 and possibly MDM2 but also a protein (kinase) activity that is
inhibited by the classic ERK kinase inhibitor PD98059 but not ERK1/2 or 5. Thus, regulation of HIF-1
activity in GCs by FSH under normoxic conditions is complex and requires input from multiple
signaling pathways. (Endocrinology 150: 915–928, 2009)
FSH acting via the G protein-coupled FSH receptor providesthe primary stimulus leading to maturation of the ovarian
follicle fromapreantral to preovulatory state (1–3). FSHbinding
to its receptor results in increases in cAMP levels and the sub-
sequent activationof proteinkinaseA leading to activationof the
cAMP response element binding protein, chromatin remodeling
via histone H3 modifications, and activation of the ERK1/2 via
inactivation of an ERKprotein-tyrosine phosphatase (4–8). The
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FSH-mediated increase in cAMP also results in up-regulation of
the phosphatidylinositol-3 (PI3)-kinase/AKT pathway (9, 10).
Recent reports have demonstrated the centrality of signaling
downstream of PI3-kinase/AKT for the induction of multiple
follicular differentiation markers (9, 11, 12). We have described
two FSH-regulated pathways downstream of PI3-kinase/AKT
and begun to elucidate their contributions to the follicular mat-
uration process. First, we have shown that in a proliferating
model of granulosa cell (GC) development downstream of FSH
and activin (13), the PI3-kinase/AKT target forkhead box O,
subfamily 1 (FOXO1) inhibits GC proliferation by serving as a
trans-acting repressor of cyclin D2 (officially Ccnd2) transcrip-
tionandinhibitsGCdifferentiationbypreventingtheup-regulation
of steroidogenic factor-1 (Nr5a1), inhibin- (Inha), aromatase
cytochrome P-450 (Cyp19a1), and epiregulin (Ereg). Therefore,
the PI3-kinase/AKT-mediated phosphorylation/inhibition of
FOXO1 is required to relieve FOXO1’s inhibitory influenceonGC
proliferation and differentiation (13).
Second, we reported that the AKT target tuberin (protein
product of the Tsc2 gene) is phosphorylated by FSH in a PI3-
kinase-dependent manner (9) at a site shown to correlate with
inhibition of its GTPase activating protein activity on the small
G protein ras homolog enriched in brain (RHEB), resulting in
increased GTP bound/active RHEB (14, 15). A downstream ef-
fector of RHEB, mammalian target of rapamycin (mTOR; offi-
cially FRAP1) (16), is then activated in GCs. Activation of
mTOR was detected by monitoring the phosphorylation of
two of its downstream targets, the 70-kDa ribosomal S6 pro-
tein (p70 S6-) kinase and eukaryotic translation initiation fac-
tor-4E binding protein (9), events that have been shown to
promote cap-dependent translation (17). We identified hyp-
oxia inducible-factor (HIF)-1 as one target of FSH-mediated
translational up-regulation downstream of the PI3-kinase/
AKT/mTOR pathway (9), a pathway that has been shown to
up-regulate HIF-1 in other cell types (18–20).
HIF-1 together with the constitutively expressed HIF-1
comprise the heterodimeric transcription factor HIF-1 (21).
HIF-1 is best known for its up-regulation in response to
hypoxic conditions that prevent its proteosomal degradation
by an E3 ubiquitin ligase complex that contains the von
Hippel-Lindau (VHL) tumor suppressor protein (22). HIF-1
can also be up-regulated under normoxic conditions in re-
sponse to growth factors that enhance protein synthesis via the
PI3-kinase pathway (23). Upon recruitment of the cAMP re-
sponse element binding protein (CREB) binding protein/p300
to its C terminus (24), HIF-1 binds to consensus hypoxia-
response elements (HRE; core -ACGTG-) in target genes char-
acteristically activated under reduced oxygen concentrations,
such as erythropoietin, glucose transporters, and various gly-
colytic enzymes, as well as in target genes that promote in-
creased vascularity including the vascular endothelial growth
factor (VEGF) receptor FLT-1 andVEGF (22). We found that
FSH treatment induced HIF-1 activity in GCs using a minimal
HRE reporter. Using a dominant-negative HIF-1 construct,
we identified inhibin-, LH receptor (Lhr, officially Lhcgr),
and VEGF as HIF-1 targets in FSH-stimulated GCs under
normoxic conditions (9).
VEGF has been characterized as an FSH target (25) and
shown to increase in expression with increasing follicle size (26,
27). Furthermore, inhibition of VEGF signaling is reported to
prevent pregnant mare serum gonadotropin (PMSG)-stimulated
antrum formation and steroidogenesis as well as thecal angio-
genesis in mice (28). Despite the increased expression of VEGF
by GCs during follicular maturation, the GC compartment re-
mains avascular until after ovulation occurs. Emerging evidence
suggests that VEGF may play a cytoprotective, autocrine role in
GCs by preventing apoptosis (29). There are also reports that
suggest that themisregulationofovarianVEGFduringovulation
induction can lead to ovarian hyperstimulation syndrome, a po-
tentially fatal complication (30, 31).
In this report we sought to further elucidate the signaling
pathways in GCs that are necessary for HIF-1 activity and the
resulting induction of VEGF. HIF-1 activity was assessed using
either a minimal HIF promoter-luciferase reporter or the VEGF-
luciferase reporter, or chromatin immunoprecipitation (ChIP)
assays with the VEGF promoter. Our results show that multiple
targets of PI3-kinase signaling in addition to mTOR-stimulated
translation contribute to the up-regulation of HIF- protein
and/or activity. These include the PI3-kinase/AKT target pro-
teins FOXO1 and mouse double-minute 2 (MDM2). However,
up-regulation of HIF-1 protein by IGF-I-mediated stimulation
of the PI3-kinase/AKT pathway is not sufficient to induce HIF-1
activity in GCs. Additional signaling downstream of a protein
whose activity is inhibited by the classic mitogen-activated ERK
kinase (MEK)1/2 inhibitor PD98059 is necessary for HIF-1 ac-
tivation, but this protein is neither MEK1/2 nor MEK5. Taken
together, these results show that regulation of HIF-1 activity in
GCs by FSHunder normoxic conditions is complex and requires
input from multiple signaling pathways.
Materials and Methods
Materials
A luciferase reporter of a trimerized 24-mer containing 18 bp from
the phosphoglycerate kinase promoter with the HRE (5-tgtcacgtcctg-
cacgactctagt-3, HRE underlined) and an 8-bp linker sequence followed
by a 50-bp minimal thymidine kinase (TK) promoter in a pGL2-basic
backbone vector (Promega, Madison, WI), HRE-(3)-TK-Luc, was pre-
viously described (32). A VEGF-luciferase reporter construct (2274 to
379) was kindly provided by Dr. Gregg L. Semenza (Johns Hopkins
School ofMedicine, Baltimore,MD) (33).Wild-type and S166D human
(H)-MDM2 expression vectors were previously described (34). Consti-
tutively active R4F mitogen-activated MEK-1 (also known as MKK1)
was kindly provided by Dr. Natalie Ahn (University of Colorado at
Boulder, Boulder, CO) (35). Recombinant human epidermal growth fac-
tor (EGF) was from Intergen (Purchase, NY). oFSH-19 was purchased
from the National Hormone and Pituitary Agency of the National In-
stitute of Diabetes and Digestive and Kidney Diseases (Torrance, CA);
PD98059, rapamycin, and LY294002 were from Calbiochem (San Di-
ego, CA); CoCl2 and anti-ERK5 antibody (E1523) were from Sigma (St.
Louis,MO); PD184352waskindly providedbyDr. SimonCook (Babra-
ham Institute, Cambridge, UK); anti-HIF-1 (H167) antibody and
anti-HIF-1 were from Novus Biologicals (Litteton, CO); anti-mTOR,
anti-AKT, anti-phospho-MDM2 (Ser166), anti-phospho-GSK3/
(Ser21/9), anti-phospho-ERK5 antibody (Thr218/Tyr220), and anti-
phospho-ERK1/2 antibody (Thr202/Tyr204) were from Cell Signaling
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Technologies (Beverly, MA); anti-FOXO1 antibody, anti-MDM2, and
anti-VEGF were from Santa Cruz Biotechnology (Santa Cruz, CA).
Animals
Sprague Dawley rats (Charles River Laboratories, Inc., Portage, MI)
were housed either at Northwestern University or Washington State
University animal care facilities and maintained in accordance with the
Guidelines for the Care and Use of Laboratory Animals by protocols
approved by the Northwestern University or Washington State Univer-
sity Animal Care and Use Committees, respectively.
PMSG treatment and tissue extract preparation
Immature female rats (26–27 d old) were injected sc with 25 IU of
PMSG. Ovaries were harvested at the indicated times after PMSG injec-
tion and subjected to tissue extract preparations, as described previously
(9). Protein concentrations weremeasured by themethod of Lowry et al.
(36) using crystalline BSA as a standard. The samples were prepared for
SDS-PAGE by suspension in sodium dodecyl sulfate (SDS)-containing
sample buffer followed by heat denaturation (100 C, 5 min). Western
blotting was performed as described below.
GC culture and Western blotting
GCs were isolated from ovaries of 26-d-old Sprague Dawley rats
primed with sc injections of 1.5 mg of estradiol-17 (E) in 0.1 ml pro-
pylene glycol on d 23–25 to promote growth of preantral follicles. Cells
were plated on fibronectin (BDBiosciences, San Jose, CA)-coated 60mm
plastic dishes at a density of about 3  106 cells/dish in DMEM/F12
serum-free medium supplemented with 1 nM E, 100 U/ml penicillin, and
100 g/ml streptomycin (E/PS), and treated with indicated additions
about 20 h after plating (7). Treatments were terminated by aspirating
mediumand rinsing cells oncewithPBS.Total cell extractswere collected
by scraping cells in SDS sample buffer (37) followed by heat denatur-
ation. Protein concentrations were controlled by plating identical cell
numbers per plate in each experiment then loading equal volumesof total
cell extract per gel lane; GCs do not proliferate under these culture con-
ditions. Equal protein loading was confirmed by total AKT or mTOR
Western blots, as indicated. GC proteins were separated by SDS-PAGE
and transferred to Hybond C-extra nitrocellulose (Amersham Bio-
sciences; Piscataway, NJ) (7). Blots were incubated with primary anti-
bodyovernight at 4C, and antigen-antibody complexeswere detected by
enhanced chemiluminescence (Amersham Biosciences). Western signals
were quantitated with Molecular Analyst/PC Image Analysis software
program (Bio-Rad Laboratories, Hercules, CA), divided by the densito-
metric signal for control protein load, and expressed relative to themax-
imal signal. Results were analyzed using Student’s t test (38).
Transfection and luciferase assays
GCs were plated in 12-well plates at 3  105 cells/ well in DMEM/
F12, E/PS. Cells were washed with PBS and transfected with various
promoter-luciferase constructs (0.5gDNA/well) and indicated expres-
sion constructs (0.05 g DNA/well) using Lipofectamine 2000 (Invitro-
gen Life Technologies, Carlsbad, CA) as described previously (39).
Briefly, cellswere incubatedwith the transfectionmixture at37Cfor4–5
h after which DMEM/F12 serum-free medium supplemented with E/PS
was added to the cells. Approximately 18–20 h after transfection, cells
were treated as indicated. Cells were lysed and analyzed for luciferase
activity using a Veritas microplate luminometer (Turner Biosystems;
Sunnyvale, CA). Data are presented as the mean  SEM of triplicate
samples. All transfection experiments were repeated aminimumof three
times with similar results. Results were analyzed using Student’s t test
(38). Percent inhibition in the presence of various inhibitors was calcu-
lated as [1  (fold inductionFSH  inhibitor/fold inductionFSH)]  100.
RT-PCR
GCs were plated in 60-mm plates at 5 106 cells/plate as described
above. The next day cells were pretreated for 1 h with 50 M PD98059
or dimethylsulfoxide (DMSO) vehicle or 0.05 M PD184352 or ethanol
vehicle and then left untreated or treated with 50 ng/ml FSH for the
indicated times, rinsed with PBS, and RNA was isolated using the
RNEasy kit (no. 74104; QIAGEN, Valencia, CA). One sixth of the total
RNA isolated was reverse transcribed for 75 min at 42 C with 1 mM
deoxynucleotide triphosphates, random hexamers (no. C118A; Pro-
mega), and avian myeloma virus-reverse transcriptase (no.M510F; Pro-
mega), and one sixth of each reverse transcriptase reaction was used for
PCR using a DNA engine cycler (Bio-Rad Laboratories, Hercules, CA)
with primers for rat VEGF or for the rat ribosomal protein L19 (VEGF
forward, 5-ctttctgctctcttgggtgcactg-3, reverse, 5-aagctcatctctcctatgt-
gctgg-3; L19 forward, 5-ctgaaggtcaaagggaatgtg-3, reverse, 5-ggaca-
gagtcttgatgatctc-3). PCRs were resolved on agarose gels containing
ethidium bromide and quantified using the Bio-Rad Quantity One pro-
gram. Results were analyzed using Student’s t test (38).
ChIP assay
ChIP assays were performed as described previously (13). Briefly,
GCs were plated in 100-mm plates at 10  106 cells/ plate in DMEM/
F12, E/PS. After various treatments, formaldehydewas added directly to
themedia for 10min at room temperature at a final concentration of 1%
to cross-link protein-DNA complexes. The cells were then washed once
with cold PBS and harvested by scraping in cold PBS with a Complete
EDTA free protease inhibitor tablet (Roche; Basel, Switzerland). The
samples were then centrifuged at 6000 rpm for 30 min. Pellets were
resuspended in 200l lysis buffer containing 1%SDS, 10mMEDTA, 50
mM Tris-HCl (pH 8), and incubated on ice for 10 min before being
sonicated for 1min. Supernatants were then recovered after samples had
been centrifuged for 10min at 14,000 rpm.A fraction of this samplewas
retained as the input. The rest was diluted 10-fold in immunoprecipita-
tion buffer containing 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA,
16.7 mM Tris-HCl (pH 8), 167 mM NaCl, and protease inhibitors. The
samples were precleared with protein A Sepharose/salmon sperm DNA
(Upstate Biotechnology, Lake Placid, NY) for 45 min. The precleared
sample was incubated with 10 l HIF-1 105 antibody (Novus-Biologi-
cals, Littleton, CO) overnight at 4 C. The immunoreactive complexes
were captured by adding protein A Sepharose/salmon sperm DNA; col-
lected by centrifugation; washed three times with 2 mM EDTA, 20 mM
Tris-HCl (pH 8), 150mMNaCl and once with Tris/EDTA; and eluted at
room temperaturewith 1%SDS and 0.1MNaHCO3.DNAwasextracted
by phenol/chloroformextraction followedby ethanol precipitation. The prim-
ers used for PCR correspond to regions in the VEGF promoter spanning a
characterized HRE: forward, 5-ggctctgtctgccag ctgtc-3 and reverse,
5-gtgacactgagaacgggaagc-3.
Samples were analyzed by real-time PCR using the Chromo4 real-time
detector (Bio-Rad). Cycle threshold [C(t)] values for each samplewere nor-
malized usingC(t)average values obtained for the corresponding input sam-
ple toobtainC(t). PCRfor each samplewasdone in triplicate.Theaverage
C(t)average was then calibrated to the sample with the highest C(t)average
(the lowest expression level) to obtain a C(t) for each sample. The nor-
malized folddifference relative to the samplewith the lowest expressionwas
then calculated using 2-C(t). Data are presented as the mean  SEM of
triplicate samples. All experiments were repeated three times with similar
results. Results were analyzed using Student’s t test (38).
Adenoviral infection of GCs
Infection with the adenovirus Ad-A3-FOXO1 or an empty adenovirus
(Ad-E)was performed as previously described (13). In short, GCswere plated
in60-mmplatesat3106cells/plate inDMEM/F12,E/PS.After thecellswere
allowed to adhere to fibronectin for 3 h, they were treated with the indicated
concentrationof adenovirus for4h.Theadenoviruswas subsequentlywashed
offwith PBS, andDMEM/F12 andE/PSwas added to the cells. The following
morning the cells underwent indicated treatments.
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Results
The contribution of the PI3-kinase pathway to
FSH-mediated HIF-1 stimulation extends beyond
increasing translation via mTOR
In this report we sought to elucidate the signaling pathways that
contribute to the ability of FSH to induce HIF-1 activity in GCs. We
previously reported that FSH inducesHIF-1 activity inGCsmeasured
both with a luciferase reporter containing 3 copies of the HRE from
phosphoglycerate kinase [HRE-(3)-TK-Luc] and with a VEGF-lucif-
erase reporter construct containing the HIF-1 binding site (9). That
FSHindeedstimulatesexpressionofVEGFmRNAandproteininGCs
is shown in Fig. 1. We also previously reported that both HRE-lucif-
erase and VEGF-luciferase activities are significantly inhibited by the
PI3-kinase inhibitor LY294002, which broadly inhibits members of
the PI3-kinase family includingmTOR (40), and by themTOR/regu-
latory associated protein of mTOR (raptor) selective inhibitor (41),
rapamycin.Furthermore,wedemonstrated thatFSH-stimulationof
GCs leads to activation of translational enhancers such as p70 S6-
kinase downstream of mTOR and that the mechanism of FSH-
mediatedup-regulationofHIF-1 isprimarily translationalandnot
transcriptional (9). However, these studies suggested that effects of
the PI3-kinase pathway were not exclusively mediated via mTOR
because the PI3-kinase/mTOR inhibitor LY294002more potently
(72%) inhibited FSH-stimulatedHIF-1 activity comparedwith the
mTOR selective inhibitor rapamycin (45%) at a concentration of
rapamycin inwhichmTORactivity, as seen by phosphorylation of
its downstream effectors, was completely abolished (9).
To identify the contribution of the PI3-kinase pathway beyond
the contributionmadebymTOR,we initially examined the relative
effect of these inhibitors onFSH-mediatedaccumulationofHIF-1
protein levels (Fig. 2). GCs were untreated (CON) or treated with
FSHfor4h inconjunctionwithvarious inhibitors.All samplesused
thehypoxiamimeticCoCl2 to inhibit thedegradationofHIF-1, as
described previously (9). Whereas the mTOR inhibitor rapamycin
inhibited FSH-mediated accumulation of HIF-1 protein by 30%
(Fig. 2, lane 2 vs. lane 8) at a dose at which the phosphorylation of
mTOR effectors was abolished (9), LY294002 inhibited the accu-
mulation ofHIF-1by 90%(Fig. 2, lane 2 vs. lane 4). These results
suggest that the greater inhibition in HIF-1 activity caused by
LY294002 relative to rapamycin that we previously reported (9) is
at least partially a result of the ability of LY294002 to cause a
greater reduction of HIF-1 protein, and that the PI3-kinase path-
way might regulate HIF-1 protein levels not only via mTOR but
also via additional pathways. We thus investigated whether there
were additional PI3-kinase targets that may play a role in FSH-
mediated HIF-1 protein accumulation in GCs.
FSH phosphorylates MDM2 at Ser166, and
phosphorylated MDM2 enhances HIF-1 activity
A PI3-kinase target reported to promote the accumulation of
HIF-1 is the ubiquitin-ligase MDM2.MDM2 is phosphorylated at
Ser166 and Ser188 byAKT (34, 42–44). AKT-mediated phosphory-
lation ofMDM2 has been shown to enhance the stability ofMDM2
by protecting it from proteosome-dependent degradation (34, 44).
Moreover, the transient expression of MDM2 in various cancer cell
models isreportedtoincreaseHIF-1activity(45)byincreasingHIF-1
protein translation (42). Studies using MDM2 in which S166 is mu-
tatedtoAsporAlademonstratethatAKT-stimulatedphosphorylation
of S166 further enhances the accumulation of HIF-1 (42). We thus
investigatedwhetherFSHpromoted theexpressionofMDM2inGCs
using anMDM2 antibody that detects total levels of MDM2 and/or
the phosphorylation of MDM2 at Ser166 using a phospho-specific
MDM2 antibody. Total MDM2 protein levels were relatively stable
over the 8-h time course of this experiment (Fig.
3A, lower panel).However,MDM2phosphory-
lation invitro inGCswasdetectedby30minpost
FSH,reachedamaximalresponseat1h,andsub-
sided by4h (Fig. 3A, top panel, lanes 3–5). FSH-
stimulated phosphorylation of AKT at Ser473
followed a similar pattern (Fig. 3A). We con-
firmedthatphosphorylationofMDM2occurred
in vivo in animals treated with a sc injection of
PMSG. Maximal MDM2 phosphorylation was
observed 8 h after PMSG andwas decreased but
still detectable at later time points (Fig. 3B). The
retarded response seen in vivo likely reflects
slower delivery of PMSG to the ovary compared
with direct addition of FSH to GCs. We further
tested the effect of overexpressing wild-type H-
MDM2 (human ortholog ofMDM2) or a phos-
pho-mimetic S166D mutant of H-MDM2 on
FIG. 1. FSH stimulates expression of VEGF mRNA and protein in GCs. A, GCs
were untreated or treated with 50 ng/ml FSH for 24 h. RNA was isolated and
subjected to RT-PCR as described in Materials and Methods using primers for
VEGF and the rat ribosomal protein L19. Results of ethidium bromide-stained
agarose gel shown are representative of three separate experiments. B, GCs were
untreated or treated with 50 ng/ml FSH for 72 h. Total cell extracts were probed
with indicated antibodies. Results are representative of three separate
experiments. CON, Control.
CON    FSH    CON    FSH   CON   FSH   CON    FSH, 4 h
HIF-1α
LY294002 PD98059 Rapamycin
mTOR
(loading control)
CoCl2
1              2           3            4          5          6           7           8
Veh
FIG. 2. The PI3-kinase/mTOR inhibitor LY294002 inhibits FSH-stimulated HIF-1 accumulation more than
the mTOR inhibitor rapamycin. GCs were pretreated with DMSO vehicle (Veh) or 12.5 M LY294002 for
1 h, 50 M PD98059 for 1 h, or 100 nM rapamycin for 15 min and then left untreated (CON) or treated
with 50 ng/ml FSH for 4 h in the presence of 150 M CoCl2 to retard degradation of HIF-1, as indicated.
Results are representative of three similar experiments. Western blots of total cell extracts were probed
with the indicated antibodies. mTOR is used as a loading control. Western signals were quantitated with
Molecular Analyst/PC Image Analysis software program, divided by the densitometric signal for mTOR,
and expressed in text relative to the untreated (CON) sample.
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HIF-1activityvia reporterassays.AlthoughH-MDM2didnot induce
a significant increase in the activity of HRE-(3)-TK-Luc, S166D H-
MDM2promoted a 3.1-fold (P0.05) increase inHRE-(3)-TK-Luc
activityoverpcDNA3-transfectedGCs(Fig.3C).Similarly,expression
of S166DH-MDM2significantly (P0.05) increased reporter activ-
ity of the HIF-1 target VEGF, measured using a VEGF-promoter-
luciferase construct (Fig. 3D), whereas the activity of the synthetic T-
cellfactorreporterTOPflash(61)wasnotaffected(Fig.3E).Thesedata
demonstrate thatMDM2isconstitutivelyexpressed in immatureGCs
andisphosphorylatedonSer166inresponsetoFSH.Theseresultsalso
show that HIF-1 activity can be positively influenced by S166D H-
MDM2 levels in GCs. Taken together, these results suggest that the
PI3-kinase/AKT target MDM2 may contribute to FSH-stimulated
HIF-1 activity in GCs.
FOXO1 inactivation by PI3-kinase/AKT phosphorylation
is necessary for FSH-mediated increase in HIF-1 protein
and HIF-1 activity
The PI3-kinase/AKT target FOXO4, a member of the fork-
head boxO containing transcription factor family, in its active
conformation has been shown to negatively affect HIF-1
stability (46). We hypothesized that the PI3-kinase/AKT tar-
FIG. 3. FSH stimulates the phosphorylation of MDM2 at Ser166; S166D H-MDM2 is sufficient to induce HIF-1 activity. A, GCs were treated with 50 ng/ml FSH for the
indicated times. Western blots of total cell extracts were probed with the indicated antibodies. Phospho (p)-specific antibodies are described in Materials and Methods.
AKT is used as a loading control. Lower two blots for total MDM2 and AKT reflect separate samples from an identical experiment. Signal for p-MDM2 was detected
about 130 and 96 kDa; signal for total MDM2 was detected about 96 kDa. Results are representative of three similar experiments. B, Rats were injected sc with 25 IU
PMSG, and ovarian extracts were prepared for Western blotting at the indicated times after PMSG injection, as described in Materials and Methods. C–E, GCs were
transfected with promoter-Luc constructs as described in Materials and Methods and with 50 ng of pcDNA3, WT-H-MDM2, or S166D-H-MDM2, as indicated. GCs
transfected with HRE-(3)-TK-Luc, VEGF-Luc, or TOPflash and the indicated expression vector were harvested 24 h after transfection. Values are expressed as a mean 
SEM of triplicates and representative of three separate experiments. Student t test for compared values: **, Significant difference with P  0.05.
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get in GCs FOXO1 might similarly regulate the stability of
HIF-1. To ascertain whether active FOXO1 affects HIF-1
accumulation in GCs, we transduced GCs either with an ad-
enovirus expressing a constitutively active mutant of FOXO1
in which the three AKT phosphorylation sites were mutated
from Thr/Ser to Ala (Ad-A3-FOXO1) or with an empty ade-
novirus (Ad-E) (13, 47). We then evaluated the accumulation
of HIF-1 in response to both FSH and, as a positive control,
the ubiquitous activator of the PI3-kinase/AKT pathway,
IGF-I. In the presence of empty adenovirus, FSH and IGF-I
enhanced the accumulation ofHIF-1 by 2.3 0.3 (n 3) and
4.6  0.7 (n  3)-fold, respectively. Expression of constitu-
tively active FOXO1mutant in GCs diminished both the FSH-
and IGF-I-mediated up-regulation of HIF-1 protein (Fig. 4A,
compare lanes 2 and 3 vs. lanes 5 and 6). Using a FOXO1
antibody, we confirmed that transduction with Ad-A3-
FOXO1 resulted in increased expression of FOXO11 (Fig. 4A,
compare lanes 1–3 and 4–6).
To ensure that the diminished accumulation of HIF-1 in the
presence of overexpressing A3-FOXO1 was not caused by a non-
specific inhibitionofAKTactivity,weassessed thephosphorylation
of glycogen synthase kinase (GSK)-3/, a recognized AKT target
(48), using a phospho-specific GSK3/ antibody. Results show
that overexpression of A3-FOXO1did not prevent AKT-mediated
phosphorylation ofGSK3/ in response to FSHor IGF-I (Fig. 4A,
compare lanes 1–3 and 4–6). The elevated phosphorylation of
GSK3 in the presence of Ad-A3 FOXO1 likely reflects the elevated
protein load in lane 5 vs. lane 2. Additionally, an inverse relation-
ship between endogenous FOXO1and the expression ofHIF-1 is
apparent in the Ad-E-treated samples (Fig. 4A, compare HIF-1
and FOXO1 levels in lanes 1–3). These results suggest that growth
factor-mediateddown-regulationofFOXO1inGCs(inresponse to
FSH or IGF-I) contributes to HIF-1 stabilization. Next we tested
the effect of the A3-FOXO1mutant onHIF-1 activity via reporter
assays inGCs transfectedwithHRE-(3)-Luc. Cotransfection of the
A3-FOXO1expressionvector significantly (P0.05) inhibited the
FSH-stimulatedactivityofHRE-(3)-TK-Lucby86%(Fig.4B).Sim-
ilarly, expression of A3-FOXO1 also significantly (P  0.05) in-
hibited FSH-mediated up-regulation of reporter activity of the
HIF-1 target VEGF, measured using a VEGF promoter-luciferase
FIG. 4. Constitutively active mutant of FOXO1 inhibits FSH-mediated up-regulation of HIF-1 and thus affects HIF-1 activity. A, GCs were allowed 3 h after isolation to
adhere to fibronectin-coated dishes and then were treated for 4 h with 5 PFU/cell of either an empty adenoviral construct, Ad-E, or Ad-A3-FOXO1, as indicated. The
following morning GCs were either untreated (CON) or treated with 50 ng/ml FSH or 50 ng/ml IGF-I for 4 h in the presence of 150 M CoCl2 as indicated. Western
blots of total cell extracts were probed with the indicated antibodies. Phospho (p)-specific antibodies are described in Materials and Methods. mTOR is used as a
loading control. B and C, GCs were transfected with promoter-Luc constructs as described in Materials and Methods and with 50 ng of pcDNA3 or A3-FOXO1, as
indicated. GCs transfected with HRE-(3)-TK-Luc (B) or VEGF-Luc (C) were left untreated (CON) or treated with 50 ng/ml FSH for 6 h. Values are expressed as a mean 
SEM of triplicates and representative of three separate experiments. Student’s t test for compared values: **, significant difference with P  0.05.
1 We previously reported increased expression of FOXO1 in GCs in-
fected with Ad-A3-FOXO1 and treated with FSH compared with con-
trols (13).
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construct, by 92% (Fig. 4C). These results indicate that the active
conformationofFOXO1, inwhich the threeAKTphosphorylation
sites are not phosphorylated, inhibits up-regulation of FSH target
genes such as VEGF by destabilizing HIF-1 and thus preventing
HIF-1 transcriptional activity.
IGF-I induces HIF- protein but not HIF-1 activity in GCs
Taken together our results show thatmultiple AKT targets,
including tuberin/mTOR (9) and FOXO1 and possibly
MDM2 contribute to FSH-stimulated HIF-1 activity in GCs.
Because IGF-I is sufficient to activate the PI3-kinase/AKT/
mTOR pathway in GCs (9) and IGF-I stimulates the accumu-
lation ofHIF-1 protein in the presence of CoCl2 (see Fig. 4A),
we asked whether IGF-I was sufficient to induce HIF-1 activ-
ity, assessed using both the minimal HIF-1 promoter-lucif-
erase construct and the HIF-1 target VEGF luciferase-pro-
moter. GCs treated for 4 h with IGF-I in the presence of CoCl2
showed a 3.4-fold accumulation of HIF-1 in IGF-I-treated
cells relative to untreated cells (Fig. 5A, lanes 3 and 4), con-
sistent with results shown in Fig. 4A. Surprisingly, however,
IGF-I was unable to stimulate HIF-1 activity relative to un-
treated (CON) GCs in reporter assays of GCs transfected with
HRE-(3)-TK-Luc (Fig. 5B, compare lanes 1 and 5), whereas
FSH consistently induced a significant activation (P  0.05)
of this reporter (Fig. 5B, compare lanes 1 and 3). This result
was unexpected because IGF-I consistently promoted a
greater accumulation of HIF-1 compared with FSH (see Fig.
4A). We also tested to see whether IGF-I synergized with FSH
to increase HIF-1 activity but found no significant difference
in HRE-(3)-TK-Luc activity in IGF-I plus FSH-treated GCs
relative to FSH-treated GCs (Fig. 5B, compare lanes 3 and 7).
Previously the sensitivity of the reporter assays allowed us to
detect the induction of HIF-1 activity by FSH in the absence
of CoCl2 (9). However, we wanted to ensure that the discrep-
ancy we detected between the ability of IGF-I to induce
HIF-1 protein by Western blots vs. the inability of IGF-I to
activate HIF-1 activity by reporter assays was not due to in-
sufficient HIF-1 protein levels. Even with the addition of the
hypoxia mimetic CoCl2 to stabilize HIF-1 levels (Fig. 5B,
hatched bars), IGF-I did not stimulate HRE-(3)-TK-Luc ac-
tivity in GCs. Similarly, reporter activity of the HIF-1 target
VEGF, measured using a VEGF promoter-luciferase con-
struct, was induced 7-fold by FSH treatment of GCs but was
unaffected by IGF-I treatment, and there was no significant
synergism between FSH and IGF-I (Fig. 5C). These data in-
dicate that the PI3-kinase pathway may be sufficient only to
promote the accumulation of HIF-1 protein in GCs but not
sufficient to stimulate HIF-1 activity. These results further
suggest that signaling events independent of the PI3-kinase
pathway that occur downstream of FSH appear to be neces-
sary to stimulate HIF-1 activity.
ERK1/2 activity does not appear to be necessary for
HIF-1 activity
There is abundant evidence fromanumber of cellmodels that
HIF-1 activity is positively regulated by ERK1/2, based largely
on effects of the MEK 1/2 inhibitor PD98059 or constitutively
activeMEK1/2, although the site of ERK1/2 phosphorylation on
HIF-1 remains controversial (49–55). Because FSH is recog-
nized to activate the ERK1/2 pathway in GCs (4), as shown in
Fig. 3A,we first askedwhether IGF-I similarly activated ERK1/2
in GCs. IGF-I promotes ERK activation in many cellular models
(53, 56, 57) but fails to do so in other cellular models as a result
of the dephosphorylation of insulin receptor substrate-1 at the
Grb2/SOS binding site by the tyrosine phosphatase Src homol-
ogy 2-containing protein phosphatase (SHP2) (58). To ascertain
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FIG. 5. IGF-I is sufficient to induce HIF- protein but not HIF-1 activity. A, GCs
were either untreated (CON) or treated with 50 ng/ml IGF-I for 4 h in the
presence or absence of 150 M CoCl2 to retard degradation of HIF-1. Western
blots of total cell extracts were probed with the indicated antibodies. AKT is used
as a loading control. B and C, GCs were transfected with promoter-Luc
constructs as described in Materials and Methods. GCs transfected with HRE-(3)-
TK-Luc (B) or VEGF-Luc (C) were left untreated (CON) or treated with 50 ng/ml
FSH, 50 ng/ml IGF-I, or 50 ng/ml FSH  50 ng/ml IGF-I for 6 h in the presence or
absence of 150 M CoCl2 as indicated. Values are expressed as a mean  SEM of
triplicates and representative of three separate experiments. Student t test for
compared values: **, significant difference with P  0.05 compared with
equivalent control.
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whether IGF-I activates ERK1/2, GCs were treated with IGF-I
for various times (leading up to, including and beyond the times
we measured HIF-1 protein levels and HIF-1 activity). Despite
robust IGF-I-stimulated phosphorylation of both AKT and
MDM2, we were unable to detect IGF-I-stimulated ERK1/2
phosphorylation (Fig. 6A).2 These results suggest that perhaps
the inability of IGF-I to induceHIF-1activity reflects the inability
of IGF-I to activate ERK1/2.
We thus sought to test the hypothesis that ERK1/2 is neces-
sary for HIF-1 activity and that the inability of IGF-I to activate
HIF-1 reflects its inability to activate ERK1/2. We first deter-
mined whether the ERK1/2 pathway was indeed necessary for
FSH to stimulate either the accumulation of HIF-1 protein
and/or induction of HIF-1 activity by treating cells without and
with the MEK1/2 inhibitor PD98059 (59). Results show that
whereas treatment of GCs with PD98059 blocked FSH-stimu-
lated ERK1/2 phosphorylation (Fig. 6B, lanes 1–4), PD98059
did not inhibit the induction of HIF-1 protein in response to
FSH (Fig. 2, compare lanes 2 and 6). However, PD98059 at the
same concentration significantly (P  0.05) inhibited the FSH-
mediated induction of HRE-(3)-TK-Luc by 72% (Fig. 6C) and
the FSH-mediated up-regulation of VEGF-Luc activity by 61%
(Fig. 6D). PD98059 also significantly (P 0.02) inhibited FSH-
FIG. 6. The selective MEK1/2 inhibitor PD98059 inhibits FSH-stimulated HIF-1 and VEGF activity, whereas the specific MEK1/2 inhibitor PD184352 does not inhibit FSH-
stimulated HIF-1 activity. A, GCs were treated with 50 ng/ml IGF-I or FSH for the indicated times. Results are representative of two similar experiments. Western blots of
total cell extracts were probed with the indicated antibodies. AKT is used as a loading control. B, GCs were pretreated with DMSO vehicle or 50 M PD98059 or with
ethanol vehicle or 0.05 M PD184352, 1 h before treatment without or with 50 ng/ml FSH for 10 min. Results are representative of three separate experiments. C and
D, GCs transfected with HRE-(3)-TK-Luc (C) or VEGF-Luc (D) were left untreated (CON) or treated with 50 ng/ml FSH for 6 h. Cells were pretreated with DMSO vehicle
or 50 M PD98059 for 1 h before control (CON) or FSH treatment. Values are expressed as a mean  SEM of triplicates and representative of three separate
experiments. Student t test for compared values: **, significant difference with P  0.05. E, GCs were pretreated for 1 h with DMSO vehicle or 50 M PD98059 or with
ethanol vehicle or 0.05 M PD184352 and then treated without or with 50 ng/ml FSH for 1 h. RNA was isolated and subjected to RT-PCR as described in Materials and
Methods using primers for VEGF and the rat ribosomal protein L19. Top panel is a representative ethidium bromide agarose gel. Lower panel shows results as mean SEM of
five separate experiments. **, significant difference with P 0.02.
2 We have observed the association of IRS1 and SHP2 in rat GCs, as
assessed by immunoprecipitation (Maizels, E., andM.Hunzicker-Dunn,
unpublished). This association may explain the unresponsiveness of the
ERK pathway to IGF-I stimulation in GCs.
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stimulated induction of VEGF mRNA by 45% (Fig. 6E). These
results thus suggest that indeed the ERK1/2 pathway contributes
to the ability of FSH to induce HIF-1 activity, but that this path-
way is not necessary for FSH to promote the accumulation of
HIF-1 protein.
Because the MEK1/2 inhibitor PD98059 disrupted only the
transactivational activity of HIF-1, and not HIF-1 accumula-
tion,we hypothesized that the ERK1/2 pathwaymaybe involved
in targetingHIF-1 to the promoters of its target genes.We there-
fore tested to seewhether the ERK1/2 pathwaywas necessary for
HIF-1 to interact with a characterized HRE in the VEGF pro-
moter. ChIP assays with a HIF-1 antibody followed by real-
timePCRusingprimers spanning anHRE in theVEGFpromoter
wereperformed.Results demonstrate that FSHtreatmentofGCs
for 4 h enhanced the interaction of HIF-1 with an HRE in the
VEGF promoter 2-fold relative to untreated GCs (Fig. 7). IGF-I
did not promote this interaction relative to untreated cells. Fur-
thermore, treatment of GCs with PD98059 prevented FSH-me-
diated HIF-1 interaction with the VEGF promoter (Fig. 7).
Based on these results, we next determined whether activating
theERK1/2pathwaywassufficient to induceHIF-1activity inGCs.
Overexpression of a constitutively active MEK1/2 mutant (R4F)
induced HRE-(3)-TK-Luc activity 16-fold compared with empty
vector inuntreatedGCs(Fig.8A,compare lanes1and2).However,
no notable additionalHRE-(3)-TK-Luc activitywas observedwith
the addition of IGF-I (Fig. 8A, compare lanes 2 and 6). R4FMEK
synergizedwith FSH treatment to further induceHRE-(3)-TK-Luc
activity beyond that observedwith either treatment alone (Fig. 8A,
lanes 3 and 4). The addition of IGF-I plus FSH did not further
enhanceHRE-(3)-TK-Luc activity over that of FSH alone (Fig. 8A,
lanes 3 and 4 vs. 7 and 8). Similarly R4F MEK significantly (P 
0.05) enhancedVEGF-Luc activity comparedwith empty vector in
untreated GCs, but did not significantly synergize with FSH or
IGF-I treatments (Fig. 8B).
Taken together, these results indicate that the ERK1/2 path-
way does not play a role in HIF-1 protein induction. Based on
results with MEK1/2 inhibitor PD98059, the ERK1/2 pathway
appears to be necessary for FSH-dependent HIF-1 transcrip-
tional activity and to be a limiting factor in FSH-dependent
HIF-1 activation. Yet ERK1/2 activity does not appear to be
sufficient to rescue IGF-I-stimulated HIF-1 activity. Thus, al-
though IGF-I enhances HIF-1 protein levels, IGF-I is unable to
direct HIF-1 to the VEGF promoter in GCs, and ERK1/2 sig-
naling cannot rescue this response.
FSH does not stimulate activation of ERK5
Based on our evidence that ERK1/2 activity was not suf-
ficient to rescue IGF-I-stimulated HIF-1 activity and on recent
evidence that PD98059 inhibits not only MEK1/2 but also
MEK5 as well as cyclooxygenases 1 and 2 (60), we hypoth-
esized that PD98059 might inhibit FSH-stimulated HIF-1 ac-
tivity by inhibiting a kinase/enzyme other than MEK1/2. To
test the hypothesis that a PD98059-sensitive enzyme/kinase
distinct from ERK1/2 might facilitate activation of HIF-1, we
evaluated the effect of a recently developed and more selective
MEK1/2 inhibitor, PD184352 (60). Results show that
whereas PD184352 indeed blocked FSH-dependent ERK1/2
phosphorylation (Fig. 6B, lanes 5–8), PD184352 did not in-
hibit FSH-stimulated HRE-(3)-TK-Luc activity (Fig. 9A) or
induction of VEGF mRNA (Fig. 6E). Similar divergent effects
of PD98059 and PD184352 on the ability of IGF-I to stimulate
HIF-1 activity in various tumor cell models was recently re-
ported (53). These results suggest that indeed FSH-stimulated
HIF-1 activity is regulated by a PD98059-sensitive kinase/
enzyme that is distinct from ERK1/2.
Based on evidence that PD98059 also inhibits MEK5 (60), we
hypothesized that perhaps FSHbut not IGF-I activatedMEK5 and
that theMEK5 target ERK5 facilitated activationofHIF-1 activity.
ERK5 activation has recently been linked to the regulation of a
number of HIF-1 targets by microarray analysis, and ERK5 and
ERK1/2 share some but not all substrates (63).We therefore tested
the hypothesis that FSH but not IGF-I may selectively activate
ERK5 to regulate HIF-1 activity and that PD98059 inhibition of
FSH-stimulatedHIF-1activitywas theconsequenceof its inhibition
of ERK5 rather than ERK1/2. Results showed, however, that FSH
did not activate ERK5, evidenced by the absence of an upshifted
band detected by a total ERK5 antibody, whereas treatment with
EGF, an established activator of ERK5 (64), promoted more than
a 3-fold activation of ERK5 (Fig. 9B). Similar resultswere obtained
using the antibody that detects phosphorylation of ERK5 at
Thr218/Tyr220. Consistent with the absence of a role for ERK5 in
regulatingHIF-1 activity inGCs, EGFdoes not stimulateHRE-(3)-
TK-Luc activity in GCs (data not shown). Taken together, these
results suggest that whereas MEK1/2 can enhance HIF-1 activity,
FSH-stimulated HIF-1 activity appears to require a protein whose
activity is inhibited by PD98059 that is distinct fromMEK1/2 and
MEK5.
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FIG. 7. Interaction of HIF-1 with the VEGF promoter is abrogated by PD98059.
ChIP assays were performed as described in Materials and Methods. GCs were
pretreated with DMSO vehicle or 50 M PD98059 for 1 h and then left untreated
(CON) and treated with 50 ng/ml FSH or 50 ng/ml IGF-I for 4 h, as indicated, in
the presence of 150 M CoCl2 to retard degradation of HIF-1. Samples were
cross-linked with formaldehyde, collected, and sonicated to fragment DNA. A
fraction was removed as input before immunoprecipitations were performed
with a HIF-1 antibody. Real-time PCR was performed on both input DNA and
immunoprecipitated DNA. C(t) values were normalized to input and then to the
CON sample. Values are expressed as a mean  SEM of triplicates and
representative of three similar experiments. Student t test for compared values:
**, significant difference with P  0.05.
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Discussion
FSH initiates a temporally defined differentiation program that
leads to maturation of the ovarian follicle, resumption of oocyte
meiosis, and subsequent ovulationof the oocyte (3). FSH induces
a number of genes that define the preovulatory phenotype in-
cluding Lhr (3), microtubule-associated protein 2D (65), in-
hibin- (66), protein kinase A type II regulatory subunit- (67),
and Cyp19a1 (68). In addition to initiating gene expression en-
compassing the up-regulation of both early (69, 70) and late
genes in the context of the differentiation program, we have
previously shown that FSH initiates an early translational event
via the PI3-kinase/AKT/mTOR pathway (9). We have also
shown how this early translational event is involved in the in-
duction of the transcription factor HIF-1 and that HIF-1 plays
a role in the up-regulation of FSH targets including LHR, in-
hibin-, and VEGF (9).
In this report, we further examined the signaling events that
are required for FSH mediated up-regulation of HIF-1 and ac-
tivation of HIF-1 and its target gene VEGF. As modeled in Fig.
10A, we show that in addition to mTOR signaling, at least one
additional target of the PI3-kinase/AKT pathway is involved in
HIF-1 activation, namely FOXO1. The transcriptional activa-
tor/repressor FOXO1 needs to be phosphorylated by AKT and
thereby inactivated for maximal FSH-mediated HIF-1 up-reg-
ulation.We previously showed that HIF-1 accumulates in GCs
in response toFSHvia increased translationandnotvia increased
transcription (9). Our observation that transduction of a con-
stitutively active FOXO1mutant into FSH-treatedGCs prevents
the accumulation of HIF-1 indicates that active FOXO1,
present normally only in the absence of FSH, must negatively
affect the stability of any HIF-1 that may be present in GCs.
Perhaps one way that HIF-1 activity is prevented in the avas-
cular follicle until FSH stimulation, even if follicle cells are ex-
periencing potential hypoxia-mediatedHIF-1 up-regulation, is
by destabilizing HIF-1 in a FOXO1-mediated manner. We
show destabilization of HIF-1 occurs even in the presence of
CoCl2 (see Fig. 4A), which is primarily thought to stabilize
HIF-1 by preventing E3 ubiquitin-ligase VHL-mediated deg-
radation (71, 72). This result suggests that FOXO1 mediates
HIF-1 degradation via a VHL-independent pathway in GCs, as
was the case for FOXO4 in a HeLa cell model (46), perhaps by
inducing a distinct ubiquitin-ligase that targets HIF-1. Further
studieswill be required todetermine themechanismbywhich the
transcriptional activator/repressor FOXO1 destabilizes HIF-1
and whether FOXO1DNA binding or transcriptional activity is
required for this activity. FOXO1might also function in GCs to
repress HIF-1 transcriptional activity by interfering with the co-
activator activity of p300, as has been recently reported for
FOXO3a (73). Further studies will also be required to determine
whether the trans-acting repressor activity of FOXO1 extends
beyond cyclin D2, steroidogenic factor-1, inhibin-, Cyp19a1,
and epiregulin (13) to include HIF-1 target genes in GCs such as
VEGF and Lhr (9).
Taken together, these results suggest that in addition to pro-
moting mTOR-stimulated translation, a further mechanism by
which FSH promotes differentiation is by affecting protein sta-
bility. Thus, HIF-1 appears to be stabilized with the phosphor-
ylation/inactivation of FOXO1 and FOXO1 protein levels are
negatively regulated by FSH treatment (see Fig. 4A).
The second PI3-kinase/AKT target in GCs that may be in-
volved in the regulation of HIF-1 activity is MDM2. MDM2 is
best known for its ability to repress the transcriptional activity of
p53 and to target p53 for ubiquitination via its E3 ligase activity
(74). MDM2 also functions independently of p53: MDM2 is
reported to promote degradation of the cell cycle inhibitor p21
independently of its ligase activity (75); to stabilize the transcrip-
tional activatorE2F1 (76); to express intrinsic chaperoneactivity
(77); to interact with ERK-phosphorylated FOXO3a leading to
FOXO3adegradation via its ubiquitin ligase activity (78); and to
enhance expression of HIF-1 (42). Phosphorylation ofMDM2
on S166 by AKT is reported to enhance p53 degradation (79),
stabilizeMDM2 (34, 42, 44), and increase expression ofHIF-1
(45) by increasing its translation rather than increasing its
half-life (42) in various cellular models. Our results constitute
the first report of the phosphorylation of MDM2 at Ser166
downstream of FSH in GCs. Phosphorylation of MDM2 on
S166 in GCs does not appear to enhance its stability; rather,
MDM2 appears to be constitutively expressed in GCs of im-
FIG. 8. Constitutively active MEK is sufficient to induce HIF-1 activity in GCs.
GCs were transfected with HRE-(3)-TK-Luc construct (A) or VEGF-Luc (B), as
described in Materials and Methods and with 50 ng of pCDNA3 or R4F-MEK, as
indicated. GCs were left untreated (CON) or treated with 50 ng/ml IGF-I, 50 ng/
ml FSH, or 50 ng/ml IGF-I  50 ng/ml FSH, as indicated, for 6 h. Values are
expressed as a mean  SEM of triplicates and representative of three separate
experiments. Student’s t test for compared values: **, significant difference with
P  0.05 between lanes 1 and 2, 1 and 3, 2 and 4, and 1 and 6 in A and
between lanes 1 and 2 and 5 and 6 in B. Lanes 2 and 6 in B are not significantly
different.
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mature follicles (see Fig. 3A).Moreover, overexpression of the
S166D H-MDM2 mutant in GCs leads to significantly in-
creased HIF-1 activity. Whereas increased HIF-1 activity
likely results at least in part from an increase in HIF-1 pro-
tein, we cannot confirm an increase inHIF-1 protein because
of the low transfection efficiency of primary GCs. It is un-
likely, however, that an increase inHIF-1 protein is sufficient
to increase HIF-1 activity, based on our results with IGF-I
(that increases HIF-1 protein but not HIF-1 activity). Thus,
the mechanism by which MDM2 increases HIF-1 activity is
not known. FSH-stimulated phosphorylation of MDM2 at
S166 may contribute to the ability of FSH to increase HIF-1
activity in GCs. However, proof that AKT-phosphorylated
MDM2 participates in FSH-stimulated activation of HIF-1
activity requires the down-regulation ofMDM2 and/or trans-
duction of GCs with adenoviral-MDM2 S166A mutant.
We further examined the role of the PI3-kinase pathway in
follicular maturation using the growth factor IGF-I. IGF-I has
been shown to play a vital role in fertility. IGF-I knockout mice
are infertile in part because of an inability to induce FSHreceptor
and to promote follicular maturation beyond the early antral
stage (80). IGF-I has also been shown to synergize with FSH in
up-regulatinganumberof folliculardifferentiationmarkers (81–
83).However, IGF-Iwasnot sufficient topromoteHIF-1 activity
despite its ability to promote accumulation of HIF-1, as de-
picted in Fig. 10	. Moreover, IGF-I did not synergize with FSH
in the induction of either HIF-1 or VEGF reporter activity. Im-
portantly, our studies begin to differentiate between the re-
sponses elicited downstream of FSH vs. IGF-I in GCs.
Both FSH and IGF-I activate the PI3-kinase/AKT pathway
leading to phosphorylation of tuberin and resulting activation of
mTOR and downstream p70 S6-kinase and eukaryotic transla-
tion initiation factor-4E (9) and accumulation ofHIF-1 (9) (see
Figs. 4 and 5), phosphorylation of GSK 3/, phosphorylation
of MDM2 (see Fig. 6A), and phosphorylation of FOXO1 (13)
(Hunzicker-Dunn, M., unpublished data) in GCs. The unex-
pected inability of IGF-I to promote HIF-1 activity and direct
HIF-1 to the VEGF promoter in GCs, despite the increase in
HIF-1 and phosphorylated MDM2 in response to IGF-I, indi-
cates that IGF-I likely regulates an additional signal that inhibits
HIF-1 activity (based on phospho-MDM2 results) and/or that
FSH regulates signals to activate HIF-1 that are not activated by
IGF-I.
Regulation of HIF-1 activity under hypoxia or normoxia via
growth factors is incompletely understood.WhereasmTOR, via
its binding partner raptor, has recently been reported to bind
HIF-1 and to increase its transcriptional activity (84), both
IGF-I and FSH activate mTOR and downstream targets, so
mTOR/raptor is unlikely to distinguish signaling between IGF-I
and FSH regarding activation of HIF-1. Many previous reports
in a variety of cellular models have demonstrated a role of the
ERK1/2 pathway in up-regulation of both HIF-1 protein levels
and/or HIF-1 activity, based almost exclusively on results using
PD98059 or constitutively active MEK1/2. Proposed roles for
ERK1/2 include a role in HIF-1 mRNA or protein up-regula-
tion (53, 55) in cooperation with the PI3-kinase pathway as
well as trans-activation by direct phosphorylation of HIF-1
or of the required coactivator p300 (49–52, 54, 85, 86). How-
ever, the phosphorylation of HIF-1 by ERK1/2 is controver-
sial and does not appear to correlate with HIF-1 activity, and
p300 phosphorylation by ERK1/2 has not been shown in an
intact cell model (54).
We found that FSH but not IGF-I activates ERK1/2 in GCs
and thus considered ERK1/2 as a potential candidate to promote
HIF-1 activation in GCs. Based on results using the MEK1/2
inhibitor PD98059 and constitutively active MEK1/2, the
ERK1/2 pathway appears to contribute to FSH stimulation of
HIF-1 activity in GCs, including the association of HIF-1 with
theVEGFpromoter, and in turn contributes to the up-regulation
of VEGF promoter-reporter activity and VEGF mRNA. The
ERK1/2 pathway, however, is not involved in FSH-mediated
induction of HIF-1 protein in GCs. However, to our surprise,
results in GCs using the recently developed and more selective
MEK1/2 inhibitor PD184352 indicate that MEK1/2 and hence
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FIG. 9. The MEK1/2-specific inhibitor PD184352 does not inhibit FSH-stimulated
HIF-1 activity. A, GCs transfected with HRE-(3)-TK-Luc were pretreated with
ethanol vehicle or with 0.05 M PD184352 for 1 h and then left untreated (CON)
or treated with 50 ng/ml FSH for 6 h. Values are expressed as a mean  SEM of
three separate experiments. B, GCs were left untreated (CON) or treated for 10
min with 50 ng/ml FSH or 50 ng/ml EGF. Total cell lysates were probed with
indicated antibodies. Results are representative of three separate experiments
(two of which are shown) except for result using p-ERK5 (T218/Y220) antibody,
which is from a single experiment.
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ERK1/2 is not necessary for FSH-stimulated HIF-1 activation
and induction of VEGFmRNA. Our results thus suggest that an
enzyme/kinase sensitive to PD98059 but distinct fromMEK1/2
is necessary to activate HIF-1 in GCs. We tested whether this
kinase could be MEK5 because this kinase is inhibited by
PD98059but not PD184352 (60), but our results show that FSH
does not activate MEK5. Thus, the PD98059-sensitive protein
(kinase) that is necessary for FSH-dependent HIF-1 activity re-
mains elusive. It is likely that this protein is selectively regulated
by FSH and not IGF-I in GCs. It is also expected that the
PD98059-sensitive protein (kinase) activity that is necessary for
HIF-1 activity in GCs is also required for HIF-1 activity in other
cell models. Further work will be necessary to identify the
PD98059-sensitive protein activity that contributes to FSH me-
diated HIF-1 activation.
We demonstrated previously (9) and in this report that CoCl2
stabilized HIF-1 protein in GCs. We used this reagent to mon-
itor the accumulation of HIF-1 because the half-life of HIF-1
under normoxic conditions is about 5min (87).However,CoCl2
like the proteosomal inhibitor MG115 (9) is not sufficient to
induce HIF-1 activity to the degree that FSH does in GCs at 6 h
nor does it synergize with FSH to activate HIF-1 (see Fig. 5B).
CoCl2 is sufficient to induce robust HIF-1 activity in other cel-
lular models (62) and is commonly thought of as a hypoxia mi-
metic. Future studieswill be required todeterminewhether phys-
iological hypoxia seen by GCs in the avascular compartment of
the follicle synergizes with FSH to up-regulate specific HIF-1
targets or perhaps acts in another manner.
In summary, our results show that the PI3-kinase pathway
has a complex role in HIF-1 induction. As summed in the
model presented in Fig. 10, we can surmise from our results
that the PI3-kinase pathway is necessary for HIF-1-mediated
up-regulation of FSH target genes such as VEGF. Our results
show that the PI3-kinase pathway is involved in HIF-1 pro-
tein up-regulation in GCs. In addition to the PI3-kinase/AKT
target mTOR, our results show that the AKT target FOXO1
in its active conformation negatively affects the accumulation
of HIF-1 in GCs. The AKT target MDM2 also increases
HIF-1 activity; however, we do not know themechanism(s) by
whichMDM2 achieves this function.We further demonstrate
the necessity of a PD98059-sensitive protein (kinase) for
HIF-1 activity independent of the PI3-kinase pathway and
show that a PD98059-sensitive protein is required to induce
binding of HIF-1 to the VEGF promoter in response to FSH.
However, this PD98059-sensitive kinase is neither MEK1/2
norMEK5. Identification of the protein activity that regulates
HIF-1 activity in GCs and likely other cells awaits future stud-
ies. Further understanding of how FSH leads to the up-regu-
lation of the transcription factor HIF-1 and target genes such
as VEGF will help us to understand the role that these target
genes play in the follicular maturation process as well as how
dysregulation of this process can lead to disease.
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